[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369350-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369350-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-ccne1-amplified-ovarian-and-endometrial-cancers-by-combined-inhibition-of-pkmyt1-and-atr","Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR","","Ovarian and endometrial cancers driven by CCNE1 amplification often resist standard therapy, creating a major unmet clinical need. Synthetic-lethal screening identifies PKMYT1 loss as selectively lethal with CCNE1 amplification, leading to a strategy combining the PKMYT1 inhibitor lunresertib (RP-6306) with the ATR inhibitor camonsertib (RP-3500/RG6526). In CCNE1-amplified patient-derived xenografts, low-dose combination treatment synergistically increases cytotoxicity, reduces metastasis, and extends survival. Mechanistically, the combination enhances CDK1 activation beyond monotherapy, triggering premature mitosis, DNA damage, and apoptosis in a CCNE1-dependent manner, supporting combined CDK1 pathway targeting as an effective therapeutic approach.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-ccne1-amplified-ovarian-and-endometrial-cancers-by-combined-inhibition-of-pkmyt1-and-atr/369350/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-ccne1-amplified-ovarian-and-endometrial-cancers-by-combined-inhibition-of-pkmyt1-and-atr/369350.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are CCNE1-amplified ovarian and endometrial cancers difficult to treat?","Question",{"text":63,"@type":64},"They often show de novo or rapid emergence of chemotherapy resistance and poor survival, and no FDA-approved drugs specifically target CCNE1-amplified cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What was the key discovery guiding the treatment strategy?",{"text":68,"@type":64},"Synthetic-lethal screening found that loss of the CDK1 regulator PKMYT1 is synthetically lethal with CCNE1 amplification, motivating combined pathway inhibition.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the combined treatment affect tumor cells mechanistically?",{"text":72,"@type":64},"Low-dose RP-6306 plus RP-3500 increases CDK1 activation, causing rapid premature mitosis, DNA damage, and apoptosis in a CCNE1-dependent manner.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369350,1790216219,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Article [https://doi.org/10.1038/s41467-025-58183-w](https://doi.org/10.1038/s41467-025-58183-w)  \nTargeting CCNE1 ampliﬁed ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR  \nReceived: 7 February 2024  \n\n| Accepted: 14 March 2025 |\n| --- |\n| |\n| Check for updates |\n\nHaineng Xu 1,2,8, Erin George1,2,6,8, David Gallo3,7,8, Sergey Medvedev1,2, Xiaolei Wang1,2, Arindam Datta4, Rosie Kryczka3, Marc L. Hyer5,  \nJimmy Fourtounis3, Rino Stocco3, Elia Aguado-Fraile5, Adam Petrone5, Shou Yun Yin3, Ariya Shiwram3, Fang Liu1,2, Matthew Anderson1,2, Hyoung Kim 1,2, Roger A. Greenberg 4, C. Gary Marshall5 &  \nFiona Simpkins 1,2   \nOvarian cancers (OVCAs) and endometrial cancers (EMCAs) with CCNE1-ampliﬁcation are often resistant to standard treatment and represent an unmet clinical need. Synthetic-lethal screening identiﬁed loss of the CDK1 regulator, PKMYT1, as synthetically lethal with CCNE1-ampliﬁcation. We hypothesize that CCNE1-ampliﬁcation associated replication stress will be more effectively targeted by combining PKMYT1 inhibitor lunresertib (RP- 6306), with ATR inhibitor camonsertib (RP-3500/RG6526). Low dose combination RP-6306 with RP-3500 synergistically increases cytotoxicity more so in CCNE1-ampliﬁed compared to non-ampliﬁed cells. Combination treatment produces durable antitumor activity, reduces metastasis and increases survival in CCNE1-ampliﬁed patient-derived OVCA and EMCA xenografts. Mechanistically, low doses of RP-6306 with RP-3500 increase CDK1 activation more so than monotherapy, triggering rapid and robust induction of premature mitosis, DNA damage, and apoptosis in a CCNE1-dependent manner. These ﬁndings suggest that targeting CDK1 activity by combining RP-6306 with RP- 3500 is an effective therapeutic approach to treat CCNE1-amplifed OVCAsand EMCAs.  \nDespite signiﬁcant progress in the last twenty years in ovarian cancer (OVCA) treatment and improved mortality rates1, this disease remains the most lethal gynecologic malignancy2. Such progress has particularly favored patients with germline or somatic BRCA1/2 pathogenic mutations or those with tumors exhibiting homologous  \nrecombination (HR) deﬁciency3,4. On the other hand, patients with HRproﬁcient tumors, particularly those with CCNE1 gene ampliﬁcation, exhibit de novo or rapid emergence of chemotherapy resistance and poor survival5,6. Endometrial cancer subtypes share molecular proﬁles with HGSOC, such as CCNE1 ampliﬁcation and TP53 mutations. There is  \n1Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 3Repare Therapeutics, Inc., 7171 FrederickBanting, Ville St-Laurent, QC, Canada. 4Department of Cancer Biology, Penn Center for Genome Integrity, Basser Center for BRCA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5Repare Therapeutics, Inc., 101 Main St, Cambridge, MA, USA. 6Present address: Department of Gynecologic Oncology, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, FL, USA. 7Present address: Department of Medicine, University of  \nWisconsin-Madison, Madison, WI, USA. 8These authors contributed equally: Haineng Xu, Erin George, David Gallo.  \ne-mail: ﬁ[ona.simpkins@pennmedicine.upenn.edu](ona.simpkins@pennmedicine.upenn.edu)  \nan increasing incidence in high-risk EMCA histologic subtypes such as uterine serous carcinoma and carcinosarcoma7, and these subtypes are among the cancers with the highest incidence of CCNE1 gene ampliﬁcation8. Further, mortality rates for endometrial cancer (EMCA) are overall increasing, and the two-fold higher risk of death from ovarian cancer compared to endometrial cancer in the early 1990s has virtually been eliminated by oppositional mortality trends1. To date, there are no FDA-approved drugs for CCNE1 ampliﬁed cancers, including OVCA and EMCA, de","cbCaikfFeo6EK7t3","https://ap.wps.com/l/cbCaikfFeo6EK7t3","pdf",4765223,"English","# Introduction\n## Clinical need in CCNE1-amplified gynecological cancers\n## Replication stress and cell-cycle checkpoint dependence\n# Mechanistic rationale\n## CDK activation and cyclin E1-driven replication control\n# Checkpoint regulator targeting\n## PKMYT1 and WEE1 roles in G2/M control\n## Therapeutic vulnerability using combined inhibition","[{\"question\":\"Why are CCNE1-amplified ovarian and endometrial cancers difficult to treat?\",\"answer\":\"They often show de novo or rapid emergence of chemotherapy resistance and poor survival, and no FDA-approved drugs specifically target CCNE1-amplified cancers.\"},{\"question\":\"What was the key discovery guiding the treatment strategy?\",\"answer\":\"Synthetic-lethal screening found that loss of the CDK1 regulator PKMYT1 is synthetically lethal with CCNE1 amplification, motivating combined pathway inhibition.\"},{\"question\":\"How does the combined treatment affect tumor cells mechanistically?\",\"answer\":\"Low-dose RP-6306 plus RP-3500 increases CDK1 activation, causing rapid premature mitosis, DNA damage, and apoptosis in a CCNE1-dependent manner.\"}]","Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR | PDF",1790182195,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/990415dd0bdc2a487b2af851d5711c32.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62e1d840d4b35ec892c4e5d001482dec.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/319fd8392748ecbdecd680dae51c66d1.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d4dee0e15dd395de430268fbee6c29f.webp",980,1301]